Germitec’s mission is to protect patients, healthcare professionals and prevent infections with innovative UV-C High-Level Disinfection devices. Chronos®, our UV-C chemical-free patented technology guarantees High-Level Disinfection (HLD) of endocavitary and external ultrasound probes in about 90 seconds without warm up, keeping workflows efficient and patient care uninterrupted. With reproducible automated cycles, 60% faster than traditional manual wipes1, discover a lower environmental footprint technology without compromising on safety. In addition, Chronos® efficacy has been proven against bacteria, fungi, viruses, mycobacteria and bacterial spores, ensuring the highest level of infection prevention. Germitec, Your partner in preventing infections.
Gerresheimer
Gerresheimer is an innovative system and solution provider and global partner for the pharma, biotech and cosmetics industries. The company offers a comprehensive portfolio of pharmaceutical packaging, drug delivery systems, medical devices and digital solutions. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. With around 13,600 employees and over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. | Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The company offers a comprehensive portfolio of pharmaceutical containment solutions, drug delivery systems and medical devices as well as solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. With 35 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. With around 12,000 employees, the company generated revenues of around €2bn in 2023. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6). www.gerresheimer.com | Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, cartridges, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma, the Group generated revenues of around EUR 2.4bn in 2024 and currently employs around 13,400 people. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6). https://www.gerresheimer.com/en/home
Genoray Co Ltd
Genoray Co., Ltd. is a company that specializes in X-Ray medical devices. As a company specializing in research, developing, manufacturing and sales, Genoray has been recognized as a leading company in the C-Arm industry in South Korea and remains a leader in this market. | Genoray America, Inc. is a company that specializes in Medical, Dental & Veterinary X-ray devices. As a company specializing in research, development, manufacturing, and sales. Genoray has been recognized as a leading company in the C-Arm industry in South Korea and remains a leader in this market.
Genomenon
Genomenon is a leading genomic intelligence company transforming patient care by uncovering the genomic drivers of genetic disease and cancer. By combining the power of AI built on the world’s premier genomic data set with genomic expertise, the company simplifies complex genetic data into actionable insights. Genomenon’s integrated software, data, and services solutions empower clients with advanced patient diagnosis and precision medicine development.
Genomic Testing Cooperative
Genomic Testing Cooperative (GTC) offers sequencing and IHC services for research projects and clinical trials. This includes all forms of sequencing and NGS applications including DNA, RNA, cfDNA and cfRNA. Projects are performed in our CAP and CLIA accredited laboratory. Our Co-Op business model has an ecosystem of labs with mirrored testing capabilities globally. GTC can support retrospective, prospective and CDx projects.
Geneyx Inc.
Geneyx’s mission is to deliver easy-to-use clinical-genetic data management and interpretation that enables hospitals and genetic labs to analyze and interpret NGS genetic reliably data at scale for patient diagnosis and R&D. Today, Geneyx Analysis (GA), our leading solution for DNA analysis and interpretation, services 200+ hospitals and labs in 50+ countries worldwide. Used by thousands of users, over 550K+ samples have already been analyzed.
GENEXTGENOMICS PVT LTD
GeNext Genomics Pvt Ltd (GNG) is one of the leading contract research, development and manufacturing organization with experience in Discovery of Novel antibodies and Biosimilar Clone development. GENEXT GENOMICS PVT LTD provides Biologics development and manufacturing services, the Cell line development and Analytics to support the Pre-Clinical Development. The Discovery Lab has propriety Antibody Library ( HINDTM – Human Immune Naive Discovery Antibody Library Platform )with highly diverse repertoire. GeNext Genomics Hyper Immune Library platform has collection of billions of antibodies against various diseases. These library are studied and for a particular target hit generation, engineering CDR’s and make recombinant antibody. The Analytical lab is equipped with high-end instruments such as BLI technology, UPLC, RT-PCR, for rapid protein analysis and characterization that allows robust and confident experimental results. The Clone development Lab is equipped with Neon Transfection, ICON a rapid plate-based titer assessment- the instrument offers rapid plate-based assessment of antibody production for cell line development using fluorescence polarization (FP). Upstream lab is equipped with for quick process development along with 2 to 50L stirred tank Bioreactors. The Downstream lab is equipped with Automated Chromatography and Tangential Flow Filtration systems. GNG has implemented a robust Quality Management System (QMS) that is meticulously designed to be phase-specific, ensuring alignment with the highest industry standards throughout the entire product lifecycle. This tailored approach enables precise compliance with the regulatory requirements for development phase. Currently company is working on 5 inhouse molecule of MAB based biosimilar with a market of 20 Billion USD, One of the molecule is at Pre-Clinical stage and has plan to complete clinical studies by 2026. GNG is funded by National Biopharma Mission, BIRAC for this molecule. Apart from Biosimilars GNG is also working in CGT and Novel discovery space with collaborative company. Under CRO, GNG is working with many clients like Nationally and Internationally for novel developments. GNG currently with an MOU with MERCK Life sciences for process development is looking forward to fast track its development of Inhouse pipeline molecule as well as supports its client for development of Novel molecule till pre-clinical developement. Apart from this GNG is manufacturer of some of the diagnostic recombinant antibodies used in Sickle cell Variant. GNG has currently 5 Biosimilar at various stages of development which is ready of Licensing. With full platform technology GNG offers Contract research services till IND filing.